BAF2437
antibody from R&D Systems
Targeting: TNFRSF25
APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF2437 - Provider product page
- Provider
- R&D Systems
- Product name
- Mouse DR3/TNFRSF25 Biotinylated Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects mouse DR3/TNFRSF25 in Western blots. In this format, approximately 5% cross-reactivity with recombinant human DR3/TNFRSF25 is observed.
- Reactivity
- Mouse
- Host
- Goat
- Conjugate
- Biotin
- Antigen sequence
AAK11256
- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells.
The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.
The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.
Expression of TNFRSF25 on conventional T cells and Tregs.
Ferdinand JR, Richard AC, Meylan F, Al-Shamkhani A, Siegel RM
Journal of immunology (Baltimore, Md. : 1950) 2018 Feb 15;200(4):1360-1369
Journal of immunology (Baltimore, Md. : 1950) 2018 Feb 15;200(4):1360-1369
The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.
Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, Cruz AC, Penumetcha P, Hayes ET, Pelletier M, Gabay O, Walsh M, Ferdinand JR, Keane-Myers A, Choi Y, O'Shea JJ, Al-Shamkhani A, Kaplan MH, Gery I, Siegel RM, Meylan F
Journal of immunology (Baltimore, Md. : 1950) 2015 Apr 15;194(8):3567-82
Journal of immunology (Baltimore, Md. : 1950) 2015 Apr 15;194(8):3567-82
The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.
Twohig JP, Marsden M, Cuff SM, Ferdinand JR, Gallimore AM, Perks WV, Al-Shamkhani A, Humphreys IR, Wang EC
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012 Aug;26(8):3575-86
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012 Aug;26(8):3575-86
Expression of TNFRSF25 on conventional T cells and Tregs.
Taraban VY, Ferdinand JR, Al-Shamkhani A
The Journal of clinical investigation 2011 Feb;121(2):463-4; author reply 465
The Journal of clinical investigation 2011 Feb;121(2):463-4; author reply 465
No comments: Submit comment
No validations: Submit validation data